
[Federal Register: July 30, 2009 (Volume 74, Number 145)]
[Notices]               
[Page 38033-38034]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30jy09-65]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-D-0324]

 
International Conference on Harmonisation; Draft Guidance on E16 
Genomic Biomarkers Related to Drug Response: Context, Structure, and 
Format of Qualification Submissions; Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the 
availability of a draft guidance entitled ``E16 Genomic Biomarkers 
Related to Drug Response: Context, Structure, and Format of 
Qualification Submissions.'' The draft guidance was prepared under the 
auspices of the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). 
The draft guidance describes recommendations regarding context, 
structure, and format of regulatory submissions for qualification of 
genomic biomarkers. The draft guidance is intended to foster 
consistency of applications across regions and facilitate joint 
discussions with and among regulatory authorities.

DATES:  Although you can comment on any guidance at any time (see 21 
CFR 10.115(g)(5)), to ensure that the agency considers your comment on 
this draft guidance before it begins work on the final version of the 
guidance, submit written or electronic comments on the draft guidance 
by September 28, 2009.

ADDRESSES:  Submit written requests for single copies of the draft 
guidance to the Division of Drug Information, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002; or 
the Office of Communication, Outreach and Development (HFM-40), Center 
for Biologics Evaluation and Research (CBER), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448. The 
guidance may also be obtained by mail by calling CBER at 1-800-835-4709 
or 301-827-1800. Send two self-addressed adhesive labels to assist the 
office in processing your requests. Submit written comments on the 
draft guidance to the Division of Dockets Management (HFA-305), Food 
and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 
20852. Submit electronic comments to http://

[[Page 38034]]

www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT:
    Regarding the guidance: Federico Goodsaid, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, rm. 2148, Silver Spring, MD 20903-0002, 301-
796-1535; or Jennifer Catalano, Center for Biologics Evaluation and 
Research (HFM-735), Food and Drug Administration, 1401 Rockville Pike, 
Rockville, MD 20852-1448, 301-827-0706.
    Regarding the ICH: Michelle Limoli, Office of International 
Programs (HFG-1), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-4480.

SUPPLEMENTARY INFORMATION:

I. Background

    In recent years, many important initiatives have been undertaken by 
regulatory authorities and industry associations to promote 
international harmonization of regulatory requirements. FDA has 
participated in many meetings designed to enhance harmonization and is 
committed to seeking scientifically based harmonized technical 
procedures for pharmaceutical development. One of the goals of 
harmonization is to identify and then reduce differences in technical 
requirements for drug development among regulatory agencies.
    ICH was organized to provide an opportunity for tripartite 
harmonization initiatives to be developed with input from both 
regulatory and industry representatives. FDA also seeks input from 
consumer representatives and others. ICH is concerned with 
harmonization of technical requirements for the registration of 
pharmaceutical products among three regions: The European Union, Japan, 
and the United States. The six ICH sponsors are the European 
Commission; the European Federation of Pharmaceutical Industries 
Associations; the Japanese Ministry of Health, Labour, and Welfare; the 
Japanese Pharmaceutical Manufacturers Association; the Centers for Drug 
Evaluation and Research and Biologics Evaluation and Research, FDA; and 
the Pharmaceutical Research and Manufacturers of America. The ICH 
Secretariat, which coordinates the preparation of documentation, is 
provided by the International Federation of Pharmaceutical 
Manufacturers Associations (IFPMA).
    The ICH Steering Committee includes representatives from each of 
the ICH sponsors and the IFPMA, as well as observers from the World 
Health Organization, Health Canada, and the European Free Trade Area.
    In June 2009, the ICH Steering Committee agreed that a draft 
guidance entitled ``E16 Genomic Biomarkers Related to Drug Response: 
Context, Structure, and Format of Qualification Submissions'' should be 
made available for public comment. The draft guidance is the product of 
the E16 Expert Working Group of the ICH. Comments about this draft will 
be considered by FDA and the E16 Expert Working Group.
    The use of biomarkers in drug discovery, development, and 
postapproval has the potential to facilitate development of safer and 
more effective medicines, to guide dose selection, and to enhance the 
benefit-risk profile of approved medicines. This draft guidance 
describes recommendations regarding context, structure, and format of 
regulatory submissions for qualification of genomic biomarkers. To 
support the evaluation of genomic biomarkers, the draft guidance 
describes and defines a submission standard applicable across regions. 
The recommendations are based on previous experiences in the various 
regions with submissions containing genomic biomarker data. Such 
submissions have been either stand-alone biomarker qualification 
applications or a component of medicinal product-related regulatory 
process. Where appropriate, the proposed document format is expected to 
facilitate incorporation of genomic biomarker data into specific 
product-related applications.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the agency's current thinking on this topic. 
It does not create or confer any rights for or on any person and does 
not operate to bind FDA or the public. An alternative approach may be 
used if such approach satisfies the requirements of the applicable 
statutes and regulations.

II. Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) written or electronic comments on the draft guidance. 
Submit a single copy of electronic comments or two paper copies of any 
mailed comments, except that individuals may submit one paper copy. 
Comments are to be identified with the docket number found in brackets 
in the heading of this document. Received comments may be seen in the 
Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.

III. Electronic Access

    Persons with access to the Internet may obtain the document at 
http://www.regulations.gov, http://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/default.htm, or 
http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

    Dated: July 23, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-18227 Filed 7-29-09; 8:45 am]

BILLING CODE 4160-01-S
